

Proposal #	Clinical trial(s) from which specimens were requested	Proposal Title	Proposal Principal Investigator/ Institution
CSC0003	E3805	HSD3B1 and Resistance to Androgen Deprivation Therapy Versus Chemohormonal Therapy in E3805	Nima Sharifi/ Cleveland Clinic Foundation
CSC0005	E2197	Proposal for Analysis of a Subset of ER+ Breast Cancer Specimens From ECOG E2197	Hannah Gilmore/ Univ. Hospitals Case Medical Center
CSC0006	E3805	Association of PTEN/ERG Status with Response to ChemoHormonal Therapy Versus Androgen Ablation on E3805	Tamara Lotan/ Johns Hopkins University
CSC0009	NCCTG N0147 NSABP C-08	Genotyping of Tumors and Patients with Stage III Colon Cancer: Identifying Genomic Markers Associated with Recurrence and Poor Outcomes (Sample Request of NCCTG N0147, NSABP C-08)	Richard Goldberg/ Ohio State University
CSC0011	S0816	Biomarkers of Early Treatment Response in Advanced Stage Classical Hodgkin Lymphoma Using Specimens From S0816	David Scott/ British Columbia Cancer Agency
CSC0013	S1107	Exome Sequencing of Tumor Tissue Samples Collected from Patients Participating in S1107 "Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ-197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma (pRCC)	Przemyslaw W. Twardowski/ City of Hope National Medical Center
CSC0014	E3805	Assessment of Gene Expression Profiles (GEP) as a Predictor of Benefit From Chemo-Hormonal Therapy in Metastatic Hormone Sensitive	Christopher Sweeney/ Dana-Farber Cancer Institute
CSC0017	RTOG 0424	Prognostic and Predictive Markers in High-Risk Low-Grade Gliomas: A Study Based On RTOG0424 (Protocol # NRG-BN-TS006)	Arnab Chakravarti/ Ohio State University
CSC0018	RTOG 9601	Association of PTEN/ERG Status with Response to Salvage Radiation Therapy with or Without Anti-Androgen Therapy: A Study of RTOG 9601	Tamara Lotan/ Johns Hopkins University

Proposal #	Clinical trial(s) from which specimens were requested	Proposal Title	Proposal Principal Investigator/ Institution
CSC0019	S0800	Immune Gene Expression Profiling of Pre-chemotherapy, Needle Biopsies and Residual Cancer Specimens from the S0800 Neoadjuvant Chemotherapy +/- Bevacizumab Trial	Lajos Pusztai/ Yale Cancer Center
CSC0025	NSABP B-31	Association of Stromal Tumor Infiltrating Lymphocytes (sTIL) with Disease Free Survival in HER2 Positive Breast Cancer Patients Enrolled in NSABP B-31	S. Rim Kim/ NRG Oncology
CSC0027	CALGB-10603	Interaction of NPM1 with FLT3 Mutations in Correlation with Host and Disease Features and Response to Induction (Daunorubicin/Cytarabine) and Consolidation (High Dose Cytarabine) Chemotherapy + Midostaurin or Placebo in the Alliance/CALGB-10603 Study.	Richard Stone/ Dana-Farber Cancer Institute
CSC0028	E3805	Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate Cancer from E3805	Christopher Sweeney/ Dana-Farber Cancer Institute
CSC0029	NCIC-MA.27	Pharmacogenomics of aromatase inhibitors in patients entered on the MA.27 clinical trial comparing anastrozole and exemestane as adjuvant therapy for early-stage postmenopausal breast cancer.	James Ingle/ Mayo Clinic
CSC0032	E1900	Precision medicine-guided PARP1 inhibitor-induced synthetic lethality in high risk AMLs from E1900 trial.	Tomasz Skorski/ Temple University
CSC0037	RTOG 0521	C-reactive Protein and the Inflammatory State: Novel Prostate Biomarkers of Aggressive Disease Using RTOG 0521 Serum Specimens	William A. Hall/ Medical College of Wisconsin

Proposal #	Clinical trial(s) from which specimens were requested	Proposal Title	Proposal Principal Investigator/ Institution
CSC0038	S0806 S0433	Impact of Mutations in Histone Acetyltransferase Genes CREBBP and EP300 on Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Vorinostat-R-CHOP in S0806, as compared to S0433 (iodine-131 tositumomab plus R-CHOP)	Catharine Smith/ University of Arizona College of Pharmacy
CSC0043	CALGB 89803	Methylated DCR1 as a novel predictive epigenetic biomarker in colon cancer cases from CALGB (Alliance) 89803	William Grady/ Fred Hutchinson Cancer Center
CSC0046	RTOG 0522	A retrospective analysis of RTOG 0522: Does myofibroblast content in the tumor-associated stroma predict response to epidermal growth factor receptor (EGFR) inhibitors in head and neck cancers	Gregory Gan/ University of New Mexico Comprehensive Cancer Center
CSC0048	E3611	Simultaneous Assessment of Biomarkers in the TME and Circulation of Metastatic Melanoma Patients Treated with Ipilimumab and Ipilimumab with Interferon-Alfa in E3611	Ahmad Tarhini/ University of Pittsburgh Cancer Institute
CSC0049	RTOG 96-01	Identifying Early Biomarkers of Anti-Androgen Treatment Resistance from the RTOG 96-01 Clinical Trial	Christopher A. Maher/ Washington University
CSC0050	RTOG 92-02 RTOG 94-13 RTOG 99-02	Discovery and Validation of Genomic Signature Predictive of Response to Long Term Androgen Deprivation Therapy (ADT) for Prostate Cancer Patients receiving Radiation Therapy as First-Line Treatment in RTOG 92-02, 94-13 and 99-02	Felix Feng/ University of California, San Francisco & Paul Nguyen/ Dana-Farber Cancer Institute/Brigham & Women's Hospital
CSC0053	RTOG 8903	Genomic Analysis of Chemoradiotherapy Response in Muscle-Invasive Bladder Tumors from completed RTOG trials: 8903, 9506, 9706, 9906, 0233, and 0524	Kent Mouw/ Dana-Farber Cancer & Jason Efsthathiou/ Massachusetts General Hospital

Proposal #	Clinical trial(s) from which specimens were requested	Proposal Title	Proposal Principal Investigator/ Institution
CSC0054	S9800 S9911 S0016	Assessing the predictive value of minimal residual disease measured by High-throughput sequencing in one year marrow specimens, for progression free survival in Follicular Lymphoma trials S9800, S9911 and S0016	Christopher Carlson/ Fred Hutchinson Cancer Center
CSC0055	E1508	Determinants of clinical outcome in small cell lung cancer using 1st line tumor samples from ECOG 1508: Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib or cixutumumab for patients with extensive stage-small cell lung cancer	Charles Rudin/ Memorial Sloan Kettering Cancer Center
CSC0064	GOG-0218	Biomarker Discovery to Direct Bevacizumab Therapy in Ovarian Cancer – Blood-based Angiome Profiling in samples from women enrolled on the Gynecologic Oncology Group (GOG) 0218 trial	Angeles Alvarez Secord/ Duke Cancer Institute
CSC0065	NSABP B-34	Protocol for the Retrospective Analysis of Maf Gene Amplification Determined by Fluorescent in Situ Hybridization in Primary Tumor Samples from the Prospective, Randomized NSABP B-34 Clinical Trial	Alexander H.G. Paterson/ Tom Baker Cancer Center, Calgary
CSC0075	RTOG 9601	Validation of a Genomic Classifier (GC) Model Prognostic of Metastasis and Biochemical Failure in a Cohort of High-Risk Prostate Cancer Patients Treated with Salvage Radiation and Anti-Androgen Therapy (AAT) after Radical Prostatectomy from the RTOG 9601 Clinical Trial	Felix Feng/ University of California, San Francisco & Phuoc T. Tran/ Johns Hopkins University
CSC0076	NSABP B-52	Assessment of critical immune markers including PD-L1, PD-1, CD8, FOXP3 and CD68 and their association with pCR in breast cancer patients enrolled into NSABP/NRG B-52 clinical trial	Katherine Pogue- Geile/ NRG Oncology

Proposal #	Clinical trial(s) from which specimens were requested	Proposal Title	Proposal Principal Investigator/ Institution
CSC0081	RTOG 9601	The telomere biomarker as a tool to inform decision-making for aggressive salvage therapy in men with rising PSA post prostatectomy in RTOG 9601	Theodore L. DeWeese, MD/ Johns Hopkins University
CSC0082	S0226	Circulating Thymidine Kinase (TK) assay and outcome within SWOG S0226	James Rae/ University of Michigan
CSC0083	RTOG 0126	Validation of a 22-Gene Genomic Classifier to Personalize Radiotherapeutic Dosing in men receiving External Beam Radiotherapy for Localized Intermediate Risk Prostate Cancer in RTOG 01-26	Daniel Spratt/ University of Michigan, Jeff Michalski/ Washington University, Felix Feng/ University of California, San Francisco
CSC0084	E3805	Somatic genomic analyses as predictors of benefit from chemo-hormonal therapy in metastatic hormone sensitive prostate cancer in E3805 CHAARTED	Christopher Sweeney/ Dana-Farber Cancer Institute
CSC0085	CALGB 40502	Intrinsic Subtype and Genomic Signatures of Response in CALGB 40502 (ALLIANCE): A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone +/- Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer	Daniel Stover/ Ohio State University
CSC0086	CALGB 40502	Tumor Infiltrating Lymphocytes as a Biomarker of Response: CALGB 40502 (ALLIANCE) A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone +/- Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer	Daniel Stover/ Ohio State University

Proposal #	Clinical trial(s) from which specimens were requested	Proposal Title	Proposal Principal Investigator/ Institution
CSC0089	RTOG 0126 RTOG 0415 RTOG 0521	Genomic Analysis of Severe, Life-Threatening Urinary and Rectal Toxicities Following Radiotherapy for Prostate Cancer in RTOG 0126, 0415, and 0521	Sarah Kern/ University of Rochester
CSC0091	NSABP B-42	NSABP B-42 clinical validation study of ESR1 mRNA by qRT-PCR as a predictor of benefit from extended adjuvant endocrine therapy with letrozole in postmenopausal women with hormone receptor positive breast cancer who have completed previous adjuvant therapy with an aromatase inhibitor	Terry Mamounas/ Orlando Health- University of Florida Health Cancer Center
CSC0092	NSABP B-42	Prediction of Benefit From Extended Adjuvant Aromatase Inhibitor (AI) Therapy and Risk Stratification for Late Distant Recurrence Using the Breast Cancer Index in Postmenopausal Women with Hormone Receptor-Positive (HR+) Breast Cancer in the NSABP B-42 Trial	Terry Mamounas/ Orlando Health- University of Florida Health Cancer Center & Priya Rastogi/ University of Pittsburgh
CSC0093	RTOG 0825	A Molecular Analysis of NRG Oncology/RTOG 0825 to Validate and Refine the Newly Developed NRGGBM-RPA as Well as Refine the New GBM Nomogram in Primary Glioblastoma Patients Treated with Radiation and Temozolomide	Arnab Chakravarti/ Ohio State University
CSC0095	S0106	Understanding and Predicting Relapse in Acute Myeloid Leukemia Using the S0106 Trial	Jerry Radich/ Fred Hutchinson Cancer Center
CSC0097	NSABP B-42	Genomic Analysis of the NSABP-B42 Extended Adjuvant Endocrine Therapy Trial cohort with the 70-gene MammaPrint Assay	Terry Mamounas/ Orlando Health- University of Florida Health Cancer Center
CSC0102	S0221	Nutrient Insufficiency and paclitaxel-induced peripheral neuropathy in SWOG 0221	Daniel Hertz/ University of Michigan

Proposal #	Clinical trial(s) from which specimens were requested	Proposal Title	Proposal Principal Investigator/ Institution
CSC0106	NSABP C-08 , CALGB 89803	Tumor stromal content as a surrogate for CMS4 molecular subtype and its association with poor prognosis in 5-FU/LV, with lack of benefit from oxaliplatin and bevacizumab in NSABP C-08, but with benefit from irinotecan in CALGB C89803 trial	Soon Paik/Yonsei University College of Medicine
CSC0108	NSABP C-08	Examination of the tumor immune microenvironment (TME) to identify markers associated with prognosis and benefit from bevacizumab in NRG Oncology/NSABP C-08: Application of multispectral fluorescent-immunohistochemistry to improve prediction of clinical outcomes in colon cancer patients	Katherine Pogue-Geile/NRG Oncology
CSC0111	RTOG 0522 RTOG-0129	Quantitative histomorphometric based image risk classifier (QuHbIC) to predict risk of progression in p16+ OP-SCC patients to be validated on RTOG 0522 and RTOG 0129	James Lewis Jr./Vanderbilt
CSC0115	NSABP B-31	Replication of genetic variants associated with cardiotoxicity in HER2+ breast cancer patients treated with chemotherapy and trastuzumab in NSABP-B31	Nadine Norton/Mayo Clinic Florida
CSC0118	RTOG 9512	Association of Oxidative Stress Pathway Alterations with Risk of Treatment Failure in RTOG9512: A Randomized Trial of Hyperfractionation Versus Conventional Fractionation in T2 Squamous Cell Carcinoma of the Vocal Cord	Quynh-Thu Le, MD/Stanford University
CSC0119	E1505	Analysis of circulating tumor DNA for detection of minimal residual disease in resected stage IB-IIIa non-small cell lung cancer patients from ECOG-ACRIN E1505	Maximilian Diehn/Stanford University

Proposal #	Clinical trial(s) from which specimens were requested	Proposal Title	Proposal Principal Investigator/ Institution
CSC0122	CALGB 89803	Evaluation of individual methylated biomarkers as novel predictive epigenetic biomarkers in colon cancer cases from CALGB (Alliance) 89803	Stacey Cohen / Fred Hutchinson Cancer Center
CSC0123	E2805	Predictive plasmatic markers of progression of patients with non-metastatic clear cell renal cell carcinoma: their influence in the efficacy of anti-angiogenic drugs administered in an adjuvant setting	Gilles Pagès/ INSERM France